Granules India Q4FY26 Revenue Up 23% YoY to ₹14,706 Mn; PAT Rises 33%
Granules India reported Q4FY26 revenue of ₹14,706 Mn, up 23% YoY. EBITDA increased 40% to ₹3,521 Mn, and PAT grew 33% to ₹2,016 Mn. For FY26, revenue was ₹53,656 Mn (+20% YoY) and PAT was ₹5,950 Mn (+19% YoY). Net debt reduced by ₹3,040 Mn YoY.
Significant YoY growth in key financial metrics like revenue and profit, along with a reduction in net debt, is likely to have a high impact on investor perception and the company's stock.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT for both the quarter and the full financial year, indicating a positive financial performance.
Granules India Limited announced its financial results for the fourth quarter and financial year ended March 31, 2026. The company reported a significant growth in revenue from operations, reaching ₹14,706 million (Mn) in Q4FY26, a 23% increase year-on-year (YoY). EBITDA also saw a substantial rise of 40% YoY to ₹3,521 Mn, and Profit Before Tax (PBT) before exceptional items grew by 48% YoY to ₹2,464 Mn. The Profit After Tax (PAT) increased by 33% YoY to ₹2,016 Mn.
For the full financial year FY26, revenue from operations stood at ₹53,656 Mn, marking a 20% YoY growth. EBITDA for FY26 was ₹11,851 Mn, up 25% YoY. PAT for the fiscal year was ₹5,950 Mn, a 19% increase YoY.
The company highlighted that its revenue share from North America was 72% in Q4FY26, while Europe contributed 17%. Finished Dosages (FD), Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Peptide/CDMO accounted for 73%, 13%, 9%, and 5% of revenue, respectively.
Return on Capital Employed (ROCE) improved to 17.6% in FY26 from 16.6% in FY25. Net debt stood at ₹4,021 Mn, a reduction of ₹3,040 Mn from Q4FY25, with a Net Debt to EBITDA ratio of 0.34x.
Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, commented, “We delivered a strong performance in Q4FY26, driven by continued portfolio expansion, disciplined execution, and steady progress across regulatory, compliance, and sustainability initiatives. The quarter reflects improving earnings quality and sustained advancement in Complex Generics and the Peptides CDMO platform.”
What to do with a filing like this
Granules India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Granules India Limited. Read the original for the full detail.